You just read:

GIOTRIF® (afatinib) approved by Health Canada as a treatment for patients with metastatic adenocarcinoma of the lung with activating EGFR mutation(s) who are tyrosine kinase inhibitor naïve

News provided by

Boehringer Ingelheim (Canada) Ltd.

Nov 07, 2013, 09:56 ET